| Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141) |
|---|
| 01/23/2003 | WO2003006500A1 Method for obtaining a tgf-beta enriched protein fraction in activated form, protein fraction and therapeutic applications |
| 01/23/2003 | WO2003006492A2 Biologically active peptides |
| 01/23/2003 | WO2003006477A1 IN VIVO PRODUCTION OF SMALL INTERFERING RNAs THAT MEDIATE GENE SILENCING |
| 01/23/2003 | WO2003006459A1 Piperazine oxime derivatives having nk-1 receptor antagonistic activity |
| 01/23/2003 | WO2003006438A1 Benzimidazole derivatives for treating microglia-activation associated diseases such as inflammatory, allergic, infectious or autoimmune diseases |
| 01/23/2003 | WO2003006433A1 Protein modification reagents |
| 01/23/2003 | WO2003006425A2 Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| 01/23/2003 | WO2003006424A1 Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| 01/23/2003 | WO2003006035A1 Anti-emetic compositions comprising mycobacterial material |
| 01/23/2003 | WO2003006028A1 Novel immunosuppressants |
| 01/23/2003 | WO2003006026A1 Combinations for the treatment of inflammatory disorders |
| 01/23/2003 | WO2003006016A2 Use of nk-1 receptor antagonists with pyridinic structure, for the treatment of brain, spinal or nerve injury |
| 01/23/2003 | WO2003006010A1 Aerosol formulations of δ8 tetrahydrocannabinol |
| 01/23/2003 | WO2003006007A1 Use of compounds as functional antagonists to the central cannabinoid receptors |
| 01/23/2003 | WO2003006003A1 Carbocyclic hydrazino inhibitors of copper-containing amine oxidases |
| 01/23/2003 | WO2003006000A1 Remedies for allergic eye diseases |
| 01/23/2003 | WO2003005988A1 Cosmetic and dermatological preparations containing creatine for treating and actively preventing dry skin and other negative alterations of the physiological homeostasis of healthy skin |
| 01/23/2003 | WO2003005960A2 Novel bicyclic and tricyclic cannabinoids |
| 01/23/2003 | WO2003005953A2 Viral proteins capable of binding lar |
| 01/23/2003 | WO2003005952A2 Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres |
| 01/23/2003 | WO2003005811A1 Il-18 transgenic animal |
| 01/23/2003 | WO2002080842A3 Medicament and method for diagnosing an autoimmune condition_in particular psoriasis |
| 01/23/2003 | WO2002072827A9 Traf3-binding b cell-specific receptor |
| 01/23/2003 | WO2002056790A3 Delivery of therapeutic capable agents |
| 01/23/2003 | WO2002050066A3 Pyrazole compounds useful as protein kinase inhibitors |
| 01/23/2003 | WO2002046171A3 Anilinopyrimidine derivatives as ikk inhibitors and compositions and methods related thereto |
| 01/23/2003 | WO2002038592A3 Peptides, the production and use thereof for binding immunoglobulins |
| 01/23/2003 | WO2002036741A3 Polynucleotide encoding an activated human t-lymphocyte-derived protein related to ubiquitin conjugating enzyme |
| 01/23/2003 | WO2002030457A3 Microbes having an attenuating mutation comprising a transcription terminator |
| 01/23/2003 | WO2002026254A3 Non-replicative particulate vaccine delivery system and methods of making and using same |
| 01/23/2003 | WO2002020619A3 HUMAN ANTIBODIES AGAINST PSEUDOMONAS AERUGINOSA LPS DERIVED FROM TRANSGENIC XENOMOUSE$m(3) |
| 01/23/2003 | WO2002020569A3 Mammalian genes; related reagents and methods |
| 01/23/2003 | WO2002018585A3 Packaging of positive-strand rna virus replicon particles |
| 01/23/2003 | WO2002017893A3 Sgk2 and sgk3 used as diagnostic and therapeutic targets |
| 01/23/2003 | WO2002011761A3 Vaccine against rsv |
| 01/23/2003 | WO2002010363A3 Protein phosphatases |
| 01/23/2003 | WO2002002607A3 Acid-modified arabinogalactan protein composition |
| 01/23/2003 | WO2001098245A3 Triphenyl compounds as interleukin-4 antagonists |
| 01/23/2003 | WO2001090358A3 Mammalian receptor proteins; related reagents and methods |
| 01/23/2003 | WO2001083782A3 Novel proteases |
| 01/23/2003 | US20030018222 Sovent extracting the dried marigold flower petals, eluting through an anion exchange resin column, diluting the eluent, crystallization; protecting lutein against deterioration, store for long time |
| 01/23/2003 | US20030018197 Administering a therapeutically effective amount of a pyrrazole sulfide or ether compound to treat the human immunodeficiency virus infection |
| 01/23/2003 | US20030018194 New Vitamin D derivatives with cyclopropyl rings in the side chains, process and intermediate products for their production and their use for the production of pharmaceutical agents |
| 01/23/2003 | US20030018193 Beta-alanine derivatives and their use as receptor anatgonists |
| 01/23/2003 | US20030018186 Monocyclic L-nucleosides, analogs and uses thereof |
| 01/23/2003 | US20030018180 Secreted protein HFEAF41 |
| 01/23/2003 | US20030018072 Utilization of dialkylfumarates |
| 01/23/2003 | US20030018040 Tumor necrosis factor antagonist; side effect reduction;antiinflammatory agents |
| 01/23/2003 | US20030018016 Cell adhesion inhibitors |
| 01/23/2003 | US20030018005 Autoimmune disease; antiinflammatory agents; antiallergens; rheumatic diseases; antitumor agents |
| 01/23/2003 | US20030017965 Methods for treating certain diseases using naaladase inhibitors |
| 01/23/2003 | US20030017617 Mammalian receptor proteins; related reagents and methods |
| 01/23/2003 | US20030017562 Nucleotide sequences coding polypetide for use in the treatment, prevention and diagnosis of gastrointestinal and apoptosis disorders |
| 01/23/2003 | US20030017527 Human vanilloid receptor-like proteins |
| 01/23/2003 | US20030017509 Methods for the diagnosis and treatment of insulin-dependent diabetes mellitus |
| 01/23/2003 | US20030017217 Extraction, purification and solvent evaporation of leaves that have been dried at </= 35 degrees C; reinforcing cellular immunity and delayed hypersensitivity in healthy humans, activating and proliferating t-lymphocytes |
| 01/23/2003 | US20030017168 Antigen delivery |
| 01/23/2003 | US20030017166 Combination preparation for the therapy of immunological diseases |
| 01/23/2003 | US20030017165 Chemically programmable immunity |
| 01/23/2003 | US20030017153 Determining whether a patient's immune system can be modified through stimulation of thymus function; sex steroids are ablated in the patient, and the resulting production of thymic factors is monitored. |
| 01/23/2003 | US20030017145 Treating subjects suffering from herpes virus infections, acquired immunodeficiency syndrome, and hepatitis C infections by administering a compound effective to inhibit the production or release of the ROMs. |
| 01/23/2003 | US20030017141 Treatment of conditions characterized by a need to modulate migratory-cell movement associated with specific sites in a subject; isolating a stromal-cell-derived fugetactic agent |
| 01/23/2003 | US20030017138 Chimeric adenoviruses |
| 01/23/2003 | US20030017120 Delivery of erectile dysfunction drugs through an inhalation route |
| 01/23/2003 | US20030017119 Aerosol comprises particles comprising at least 10 percent by weight of an opioid, and wherein the opioid is not heroin; opiods include morphine, codeine, naltrexone, buprenorphine, fentanyl, nalbuphine, naloxone, etc. |
| 01/23/2003 | US20030017118 An aerosol for inhalation therapy, wherein the aerosol comprises particles comprising at least 10 percent by weight of an antipsychotic such as olanzapine, trifluoperazine, haloperidol, loxapine, clozapine, quetiapine, promazine, etc. |
| 01/23/2003 | US20030017117 Delivery of analgesics through an inhalation route |
| 01/23/2003 | US20030017116 Delivery of sedative-hypnotics through an inhalation route |
| 01/23/2003 | US20030017115 Aerosol comprises particles comprising at least 10 percent by weight of a drug ester. |
| 01/23/2003 | US20030017114 Aerosol comprises particles of chlordiazepoxide, betahistine, clonidine, testosterone, conjugated estrogens, estrogen esters, estradiol, estradiol esters, ethinyl estradiol, ethinyl estradiol esters, or hyoscyamine. |
| 01/23/2003 | US20030015190 Delivery of compounds for the treatment of migraine through an inhalation route |
| 01/23/2003 | US20030015189 Delivery of antihistamines through an inhalation route |
| 01/23/2003 | CA2707767A1 Biologically active peptides |
| 01/23/2003 | CA2453566A1 Method and composition for inhibiting heparanase activity |
| 01/23/2003 | CA2453399A1 Combinations for the treatment of inflammatory disorders |
| 01/23/2003 | CA2453389A1 Aerosol formulations of .delta.8 tetrahydrocannabinol |
| 01/23/2003 | CA2453183A1 In vivo production of small interfering rnas that mediate gene silencing |
| 01/23/2003 | CA2452491A1 Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| 01/23/2003 | CA2452417A1 Compositions comprising the biologicially active peptide ysl |
| 01/23/2003 | CA2452382A1 Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres |
| 01/23/2003 | CA2451569A1 Carbocyclic hydrazino inhibitors of copper-containing amine oxidases |
| 01/23/2003 | CA2451566A1 Use of nk-1 receptor antagonists for the treatment of brain, spinal or nerve injury |
| 01/23/2003 | CA2446726A1 Piperazine oxime derivatives having nk-1 receptor antagonistic activity |
| 01/23/2003 | CA2434303A1 Method for obtaining a tgf-beta enriched protein fraction in activated form, protein fraction and therapeutic applications |
| 01/23/2003 | CA2417156A1 3,4-dihydroisoquinoline derivative compound and a pharmaceutical agent comprising it as active ingredient |
| 01/22/2003 | EP1277764A2 Allergenic proteins and peptides from dog dander and uses therefor |
| 01/22/2003 | EP1277747A1 Selective preventives/remedies for progressive lesions after organ damage |
| 01/22/2003 | EP1277743A1 Oxa(thia)zolidine derivative and anti-inflammatory drug |
| 01/22/2003 | EP1277729A1 Ppar (gamma) modulators |
| 01/22/2003 | EP1277057A2 Screening method for compounds |
| 01/22/2003 | EP1276902A2 Methods and materials relating to carcinoembryonic antigen-like (cea-like) polypeptides and polynucleotides |
| 01/22/2003 | EP1276872A2 A thymus expressed human cytochrome p450 (p450tec) |
| 01/22/2003 | EP1276856A1 Albumin fusion proteins |
| 01/22/2003 | EP1276853A1 Pneumovirus ns proteins antagonising the interferon (ifn) response |
| 01/22/2003 | EP1276849A2 Albumin fusion proteins |
| 01/22/2003 | EP1276764A1 Human polynucleotides, polypeptides, and antibodies |
| 01/22/2003 | EP1276761A2 New bromodomain protein |
| 01/22/2003 | EP1276755A1 Novel compounds |
| 01/22/2003 | EP1276739A2 Heterocycles that are inhibitors of impdh enzyme |
| 01/22/2003 | EP1276734A1 Halogenated rhodamine derivatives and applications thereof |